Long-Term Results of Trabeculectomy With Different Concentrations of Mitomycin C in Refractory Developmental Glaucoma

Purpose: To evaluate the long-term results of trabeculectomy with two different concentrations of mitomycin C in refractory developmental glaucoma. Patients and Methods: A total of 48 eyes of 37 patients with previous failure of congenital glaucoma surgery underwent mitomycin C-augmented trabeculectomy. Data were analyzed retrospectively, and patients were divided into two groups. Group 1 consisted of 18 patients (25 eyes) who underwent trabeculectomy with a 0.4-mg/mL mitomycin C solution and group 2 consisted of 19 patients (23 eyes) who underwent trabeculectomy with a 0.2-mg/mL mitomycin C solution. Pre- and postoperative intraocular pressure (IOP), best-corrected visual acuity, bleb characteristics, success rate, and complications were compared for both groups. Results: Mean time between primary surgery and mitomycin C-augmented trabeculectomy was 19.3 months (range, 11 months to 7 years). Mean preoperative IOP was 28.4 ± 2.9 mm Hg in group 1 and 29.0 ± 2.4 mm Hg in group 2. Final postoperative IOP was 17.0 ± 1.6 for group 1 and 17.1 ± 1.4 mm Hg for group 2. There were no significant differences between the groups for IOP, success rate, and complications ( P > .05). The most common postoperative complication was shallow anterior chamber (11 [22.9%] of 48 eyes). Conclusions: A 0.4- or 0.2-mg/mL mitomycin C solution for 4 minutes may be used during trabeculectomy in refractory developmental glaucoma. J Pediatr Ophthalmol Strabismus 2005;42:97–102.